Cancer

Lynx.MD Builds Massive Gastroenterology (GI) Data Repository for Research and AI Development

Providing Real-World Data for Life Science and Medtech AdvancementsPALO ALTO, CA / ACCESSWIRE / January 24, 2024 / Lynx.MD, a…

12 months ago

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS…

12 months ago

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine…

12 months ago

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

12 months ago

Kura Oncology Announces Oversubscribed $150 Million Private Placement

– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma…

12 months ago

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

         PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted…

12 months ago

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicityCRL does not impact commercial availability of…

12 months ago

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

         PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted…

12 months ago

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to…

12 months ago